[
  {
    "ts": null,
    "headline": "FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment",
    "summary": "Biogen and Eisai won Food and Drug Administration approval of an at-home shot version of their Alzheimer's treatment Leqembi.",
    "url": "https://finnhub.io/api/news?id=8ac325eaebc6ca62bbd8cd12edd6a0b694688f2cd3f5b93dc6f505b44671057d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756501228,
      "headline": "FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment",
      "id": 136579816,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen and Eisai won Food and Drug Administration approval of an at-home shot version of their Alzheimer's treatment Leqembi.",
      "url": "https://finnhub.io/api/news?id=8ac325eaebc6ca62bbd8cd12edd6a0b694688f2cd3f5b93dc6f505b44671057d"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIKTM, pronounced \"I Click\") for maintenance dosing. LEQEMBI IQLIK is a subcutaneous autoinjector (SC-AI) developed by Ei",
    "url": "https://finnhub.io/api/news?id=59e87c964602bcc8bccce301c15d9e6109a1550b0ffefc9f8e0a17563c32f3d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756501200,
      "headline": "FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease",
      "id": 136579817,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIKTM, pronounced \"I Click\") for maintenance dosing. LEQEMBI IQLIK is a subcutaneous autoinjector (SC-AI) developed by Ei",
      "url": "https://finnhub.io/api/news?id=59e87c964602bcc8bccce301c15d9e6109a1550b0ffefc9f8e0a17563c32f3d9"
    }
  },
  {
    "ts": null,
    "headline": "Biogen, Eisai Get FDA Approval for Injectable Alzheimer's Treatment",
    "summary": "Biogen, Eisai Get FDA Approval for Injectable Alzheimer's Treatment",
    "url": "https://finnhub.io/api/news?id=bfb26a7270db6d5d83561dcc5fe1721e94b74354fbc4373ab4320d044b41665e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756489200,
      "headline": "Biogen, Eisai Get FDA Approval for Injectable Alzheimer's Treatment",
      "id": 136725609,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen, Eisai Get FDA Approval for Injectable Alzheimer's Treatment",
      "url": "https://finnhub.io/api/news?id=bfb26a7270db6d5d83561dcc5fe1721e94b74354fbc4373ab4320d044b41665e"
    }
  }
]